III. Emlőrák Konszenzus Konferencia – Sugárterápiás irányelvek

The radiotherapy expert panel revised and updated the radiotherapy (RT) guidelines accepted in 2009 at the 2nd Hungarian Breast Cancer Consensus Conference based on new scientific evidence. Radiotherapy of the conserved breast is indicated in ductal carcinoma in situ (St. 0), as RT decreases the risk of local recurrence by 60%. In early stage (St. I-II) invasive breast cancer RT remains a standard treatment following breast conserving surgery. However, in elderly (>/=70 years) patients with stage I, hormone receptor positive tumour hormonal therapy without RT can be considered. Hypofractionated (15x2.67 Gy) whole breast irradiation and for selected cases accelerated partial breast irradiation are validated treatment alternatives of conventional (25x2 Gy) whole breast irradiation. Following mastectomy RT significantly decreases the risk of locoregional recurrence and improves overall survival of patients having 1 to 3 (pN1a) or >/=4 (pN2a, pN3a) positive axillary lymph nodes. In selected cases of patients with 1 to 2 positive sentinel lymph nodes axillary dissection can be omitted and substituted with axillary RT. After neoadjuvant chemotherapy (NAC) followed by breast conserving surgery whole breast irradiation is mandatory, while after NAC followed by mastectomy locoregional RT should be given in cases of initial stage III-IV and ypN1 axillary status

Áttétes vesedaganatos betegek everolimusterápiájával szerzett hazai tapasztalatok

Everolimus is indicated for the therapy of adults with advanced renal cell carcinoma after failure of treatment with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). The aim of the study was a multicenter evaluation of efficiency and toxicity of everolimus in patients with metastatic renal carcinoma who received one line of VEGFR-TKI therapy. Data of one hundred and one patients were analyzed retrospectively. Patients received everolimus therapy between January 2010 and July 2013. Data were collected in 7 different oncology institutes in Hungary. Starting daily dose of everolimus was 10 mg in 28-day cycles. Physical and laboratory examinations were done monthly. Imaging tests were performed every 3 months. Tumor response and toxicity were evaluated according to RECIST 1.0 and NCI CTCAE 3.0, respectively. Statistical analysis was performed with SPPS version 20.0 for Windows. Currently 26 (27%) patients are being treated, 52 (54.1%) patients are alive. Median progression-free survival (PFS) was 5.7 months (95% CI 4.07-7.33). Partial remission, stable disease and progression occurred in 6 (6%), 71 (74%) and 19 (20%) patients, respectively. Median overall survival (OS) was 14.3 months (95% CI 6.99-19.81). PFS and OS results were more favorable in patients with ECOG 0-1. Survival was poorer in case of anemia, while better if PFS was longer than 12 months. In anemic patients with ECOG 0-1 and ECOG 2-3 OS was 30.9 and 7.7 months, respectively (p=0.031). Dose reduction and treatment delay happened in 8 (7.9%) and 12 (11.9%) cases, respectively. The most common side effects were the following: exanthema, edema, stomatitis, pneumonitis, anemia and abnormal kidney-, liver functions, blood sugar and cholesterol levels. According to the Hungarian experience, everolimus can safely be administered. PFS and OS results representing the centers' everyday practice, are similar to the results of the respective subgroups in the registration study

Az első tapasztalatok a palliatív onkoteamrendszer működésével kapcsolatban a Pécsi Tudományegyetemen

Bevezetés és célkitűzés: Az előrehaladott, áttétes daganatos betegek megfelelő tüneti és életvégi ellátása, illetve ennek elérése komoly kihívás minden egészségügyi ellátó számára. A palliatív onkoteamrendszer kialakításával célunk a be- tegek időbeni palliatív ellátásba vonása és a konzekvencia nélküli sürgősségi kivizsgálások és ellátások számának lehe- tőség szerinti csökkentése volt. Módszer és eredmények: A palliatív onkoteam megbeszéléseit kéthetente tartottuk meg; a team állandó tagjai palliatív szakorvos, onkológus, belgyógyász, pszichiáter, szakápoló, pszichológus voltak, de időszakosan más szakemberek is csatlakoztak. 2019 májusa és 2020 januárja között 93, előrehaladott stádiumú daganatos betegnél 97 eseti megbe- szélést tartottunk, egy-egy ülésen 6–10 beteg esetét tárgyaltuk végig. Minden esetben meghatároztuk a beteg továb- bi palliatív ellátásának formáját (szakrendelésen jelentkezés, otthoni szakellátás, intézeti elhelyezés) és azt, hogy adott esetben még szóba jön-e további aktív onkológiai ellátás. A megbeszélésre került betegek esetében pár hónap eltelte után a felesleges sürgősségi megjelenések számában egyértelmű csökkenés mutatkozott. Következtetés: A kezdeti, sokszor heves érzelmekkel is kísért megbeszélések rövid időn belül komoly operatív szakmai fórummá váltak. Úgy gondoljuk, hogy ez a rendszer is komolyan hozzájárulhat ahhoz, hogy az előrehaladott daga- natos betegek időben palliatív szakellátáshoz jussanak, és ahhoz is, hogy a gyógyító onkológiai attitűd fokozatosan segítő orvosi hozzáállássá tudjon válni

Áttétes vesedaganatos betegek kabozantinibterápiájának multicentrikus magyarországi eredményei

The aim of our analysis was to evaluate the efficacy of cabozantinib in patients with metastatic renal cell carcinoma. Cabozantinib therapy initiated between 01/01/2019 and 31/12/2022 was evaluated based on a retrospective review of data from 14 renal centers in Hungary. The starting dose was 60 or 40 mg. Physical examinations and laboratory tests were performed every 4 weeks and imaging studies 3-monthly. Tumor response was assessed according to RECIST 1.1, and toxicity according to NCI CTCAE 4.0. A total of 230 patient records were evaluated, 201 (87.4%) of them had clear cell RCC. Cabozantinib was administered as third, second and first-line treatment in 48.7%, 38.3% and <5% of cases, respectively. Dose reductions occurred in 62.6% and treatment interruption in 6.5%. Duration of therapy was 10.03 months, which was independent of dose reduction. Overall tumor response rate was 39.2% and clinical benefit was 82.8%. The duration of first-, second-, third- and fourth-line treatment was 11.47, 8.03, 11.57 and 10.13 months, respectively. Overall survival from the start of therapy was 22.0 months. Cabozantinib therapy in daily practice was more beneficial than according to registry study results. Dose reduction did not affect efficacy